CALQUENCE® (acalabrutinib) Clinical Insights from a Real-World Patient with Treatment Naive CLL скачать в хорошем качестве

CALQUENCE® (acalabrutinib) Clinical Insights from a Real-World Patient with Treatment Naive CLL

Please see full Prescribing Information: https://bit.ly/32ycnxx This video is intended for US healthcare professionals only. Dr Nilanjan Ghosh and Dr Tara Graff present a clinical case of a patient with treatment naive CLL who was treated with CALQUENCE. How the patient’s diagnosis, clinical history, genetic biomarker status, and comorbidities are used in determining the treatment plan is presented. The results of the ELEVATE-TN clinical trial of CALQUENCE in patients with treatment naive CLL are discussed in relation to the patient case. Indication and Usage CALQUENCE is indicated for the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Select Safety Information Serious adverse events, including fatal events, have occurred with CALQUENCE, including serious and opportunistic infections, hemorrhage, cytopenias, second primary malignancies, and atrial fibrillation and flutter. The most common adverse reactions (≥ 30%) of any grade in patients with CLL were anemia, neutropenia, thrombocytopenia, headache, upper respiratory tract infection, and diarrhea.